Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17556987 | 0.94 | ALDH1A1 (0.53) | ALDH1A1ESR2APPNAAAHDAC1 | |
| SCHEMBL10370708 | 0.94 | ALDH1A1 (0.53) | ALDH1A1ESR2APPNAAAHDAC1 | |
| SCHEMBL24214590 | 0.91 | ESR2 (0.47) | ALDH1A1ESR2APPESR1CYP3A4 | |
| SCHEMBL19189535 | 0.83 | ALDH1A1 (0.49) | ALDH1A1ESR2APPESR1CYP3A4 | |
| SCHEMBL11437886 | 0.82 | SLC18A3 (0.52) | ALDH1A1 | |
| SCHEMBL23039947 | 0.82 | ALDH1A1 (0.43) | ALDH1A1ESR2APPNOS3NOS1 | |
| SCHEMBL8053564 | 0.81 | QDPR (0.53) | ALDH1A1ESR2ESR1HDAC1HDAC8 | |
| SCHEMBL18702848 | 0.78 | NOS3 (0.36) | ALDH1A1ESR2NOS3NOS1HPGD | |
| SCHEMBL11213083 | 0.77 | HPGD (0.50) | ALDH1A1APPNAAAHDAC1HDAC8 | |
| SCHEMBL5886587 | 0.76 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | ALDH1A1 4846/4885ESR2 784/4885APP 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.